Clinical Trial Update: Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease [Phase 3]

View source ↗

Summary

Phase 3 trial update characterizing 24-hour lung function profiles of the inhaled tiotropium + olodaterol fixed-dose combination in chronic obstructive pulmonar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Spiriva (tiotropium)
• Striverdi Respimat (olodaterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2015-07-16